Table 2.

Summary of Participant Characteristics at Baseline Stratified by Treatment Condition and Completer Status

Variable	Placebo			Topiramate
	Full	Completers	Attriters	Full	Completers	Attriters
N	26 (39.4)	20 (76.9)	6 (23.1)	40 (60.6)	19 (47.5)	21 (52.5)
Age	18.81 ± 2.08*	18.70 ± 2.27	19.17 ± 1.33	20.30 ± 2.03*	20.16 ± 2.27	20.43 ± 1.83
Male	12 (46.2)	9 (45.0)	3 (50.0)	20 (50.0)	9 (47.4)	11 (52.4)
Minority	13 (50.0)	9 (45.0)	4 (66.7)	19 (47.5)	12 (63.2)	7 (33.3)
Overall IQ	96.85 ± 13.60	98.15 ± 13.12	92.50 ± 15.53	102.80 ± 17.18	97.84 ± 15.07	107.29 ± 18.08
BDI score	6.08 ± 8.50	5.25 ± 6.54	8.83 ± 13.69	4.55 ± 5.08	5.68 ± 5.23	3.52 ± 4.83
Baseline cannabis problems	25.46 ± 23.30	20.05 ± 13.64	43.50 ± 38.73	20.08 ±16.86	24.74 ± 20.07	15.86 ± 12.35
Baseline percent use days	70.94 ± 28.60	66.78 ± 30.00	84.81 ± 19.02	70.22 ± 26.89	70.29 ± 27.11	70.16 ± 27.46
Baseline grams per use day	0.88 ± 0.73	0.86 ± 0.69	0.93 ± 0.91	0.53 ± 0.37	0.62 ± 0.46	0.45 ± 0.25

Note. BDI = Beck Depression Inventory. All variables were measured at baseline. Tabled values for categorical variables are count (%), whereas values for continuous variables are mean ± standard deviation. Differences in categorical variables were calculated via chi-square tests, whereas differences in continuous variables were calculated via independent sample t-tests. Significant column differences based on bias-corrected 95% confidence intervals with 1000 bootstrap draws and noted by superscript letters.

^*M_difference = − 1.49, t(64) = −2.89, p = .005, SE = .52, 95%CI [− 2.52, − 0.46]